Downmodulation of bFGF-binding protein expression following restoration of p53 function

Cancer Gene Therapy

Volumn 8, Issue 10, 2001, Pages 771-782

  Sherif, Z A ^a   Nakai, S ^a   Pirollo, K F ^a   Rait, A ^a   Chang, E H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antiangiogenesis; bFGF binding protein; p53; Tumor regression

Indexed keywords

ANGIOGENIC FACTOR; BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR REGRESSION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL DIVISION; COLLAGEN; DNA PRIMERS; DOWN-REGULATION; DRUG COMBINATIONS; HEAD AND NECK NEOPLASMS; HUMANS; LAMININ; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; ANIMALIA;

EID: 0034780683     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700361     Document Type: Article

References (73)

1. What is the evidence that tumors are angiogenesis-dependent?
2. Growth factors in angiogenesis: Current interest and therapeutic potential
3. Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis
4. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression
5. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin
6. Development of angiogenesis inhibitors for cancer therapy
7. The transforming growth factor-beta signaling pathway in tumorigenesis
8. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis
9. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
10. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
11. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts
12. Biological and clinical importance of the p53 tumor suppressor gene
13. The heparin-binding (fibroblast) growth factor family of proteins
14. Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property
15. Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family
16. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor
17. Both normal and tumor cells produce basic fibroblast growth factor
18. Basic fibroblast growth factor as a growth inhibitor for cultured human tumor cells
19. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis
20. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor
21. Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix
22. Fibroblast growth factor in the extracellular matrix of dystrophic (MDX) mouse muscle
23. Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: Implications for a role of heparinase-like enzymes in the neovascular response
24. Basic fibroblast growth factor binds to subendothelian extracellular matrix is released by heparitinase and heparin-like molecules
25. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors
26. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors
27. Tissue distribution and retinoid-mediated downregulation of an FGF-binding protein (FGF-BP) in the rat
28. Structural characterization of the fibroblast growth factor binding protein purified from bovine prepartum mammary gland secretion
29. P53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
30. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector
31. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
32. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect."
33. Gene therapy of hepatoma: Bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir
34. Assessment of bystander effect potency produced by intratumoral implantation of hsvtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics
35. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
36. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma
37. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene
38. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
39. "Bystander killing" induces apoptosis and is inhibited by forskolin
40. Novel method for selective killing of transformed rodent cells through intracellular communication, with possible therapeutic applications
41. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
42. Gene therapy of cancer
43. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
44. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer
45. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
46. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
47. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck
48. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells
49. Radio-resistant tumor cells are present in head and neck carcinomas that recur after radiotherapy
50. Adenovirus-mediated expression of therapeutic plasma levels of human Factor IX in mice
51. Adenoviral vectors for gene transfer
52. Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA
53. Inhibition of retinoblastoma (Rb) protein phosphorylation by the combined effect of interferon-α and tumor necrosis factor-α
54. Induction of the growth inhibitor IGF-binding protein 3 by p53
55. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
56. The tumor suppressor p53 regulates its own transcription
57. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
58. How tumors become angiogenic
59. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
60. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
61. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
62. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
63. A secreted FGF-binding protein can serve as the angiogenic switch for squamous cell carcinoma
64. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer
65. Induction of the angiogenic modulator fibroblast growth factor binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways
66. Phorbol ester-induced transcription of a fibroblast growth factor binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements
67. Insulin-like growth factor (IGF) binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism
68. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
69. Insulin-like growth factor binding protein 3 (IGFBP-3): A novel target of the tumor suppressor p53 inhibiting cell growth
70. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer
71. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer
72. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent
73. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma